FGF23 and Cause-Specific Mortality in Community-Living Individuals—The Health, Aging, and Body Composition Study

Shilpa Sharma, Ronit Katz, Ruth F. Dubin, David A. Drew, Orlando M. Gutierrez, Michael G. Shlipak, Mark J. Sarnak, Joachim H. Ix

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Objectives: Fibroblast growth factor (FGF)-23 is a key regulator of mineral metabolism and has been linked with left ventricular hypertrophy in animal models. Most existing epidemiologic studies evaluated a C-terminal FGF23 assay which measures both the intact (active) hormone and inactive fragments. The relationship of intact FGF23 with cause-specific mortality is unknown. Design: Prospective analyses of data from Health, Aging, & Body Composition (HABC) study. Setting: Community-living adults aged 70 to 79 years with longitudinal follow up.

Original languageEnglish (US)
Pages (from-to)711-717
Number of pages7
JournalJournal of the American Geriatrics Society
Volume69
Issue number3
DOIs
StatePublished - Mar 2021
Externally publishedYes

Keywords

  • assays
  • cause-specific
  • FGF23
  • mortality

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint

Dive into the research topics of 'FGF23 and Cause-Specific Mortality in Community-Living Individuals—The Health, Aging, and Body Composition Study'. Together they form a unique fingerprint.

Cite this